Clinical Effects of Pomalidomide-Based Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2025.02.017
- Author:
Man YANG
1
;
Yan HUANG
1
;
Ling-Xiu ZHANG
1
;
Guo-Qing LYU
1
;
Lu-Yao ZHU
1
;
Xian-Kai LIU
1
;
Yan GUO
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory of Lymphoma Molecular Diagnosis and Treatment, Xinxiang 453100, Henan Province, China.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
relapsed and refractory;
pomalidomide;
clinical effect
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Thalidomide/administration & dosage*;
Dexamethasone/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Female;
Male;
Middle Aged;
Recurrence;
Aged;
Cyclophosphamide/therapeutic use*;
Treatment Outcome;
Antibodies, Monoclonal
- From:
Journal of Experimental Hematology
2025;33(2):431-436
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical effects of pomalidomide-based regimen in the treatment of relapsed and refractory multiple myeloma (RRMM).
METHODS:60 patients with RRMM in hematology department of the First Affiliated Hospital of Xinxiang Medical University from November 2020 to January 2023 were selected. Among them, 15 cases were treated with PDD regimen (pomalidomide + daratumumab + dexamethasone), and 45 cases were treated with PCD regimen (pomalidomide + cyclophosphamide + dexamethasone). The clinical effects were evaluated.
RESULTS:The median number of treatment cycles for the entire cohort was 5 (2-11), with an overall response rate (ORR) of 75.0%. The ORR of patients treated with PDD regimen was 73.3%, while the ORR of patients treated with PCD regimen was 75.6%. The ORR of 46 patients with non high-risk cytogenetic abnormalities (non-HRCA) was 86.9%, significantly higher than the 35.7% of 14 patients with HRCA (χ2 =15.031, P < 0.05). The median PFS for all patients was 8.0(95%CI : 6.8-9.1) months and the median OS was 14.0 (95%CI : 11.3-16.7) months. Among patients treated with PDD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 7.0(95%CI : 4.6-9.3) months vs 4.0(95%CI : 3.1-4.8) months, χ2 =5.120, P < 0.05; OS: not reached vs 6.0(95%CI : 1.1-10.9) months, χ2 =9.870, P < 0.05]. Among patients treated with PCD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 9.0(95%CI : 6.2-11.8) months vs 6.0(95%CI : 5.4-6.6) months, χ2=14.396, P < 0.05; OS: not reached vs 11.0(95%CI : 6.4-15.6) months, χ2 =7.471, P < 0.05].
CONCLUSION:The pomalidomide-based regimen has a good clinical effect and safety in the treatment of RRMM.
